Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Toggle navigation
Contact Us
Subscribe
Promote Your Event
e-Edition
Privacy Policy
Terms of Service
Local Weather
Home Delivery
Submission Forms
News
Local News
The Leader
Heartland News
Sports
Entertainment
Local Events
Multimedia
Photo Galleries
Videos
Obituaries
Classifieds
Real Estate
Property for Rent
Cars & Vehicles
Jobs
Items for Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place an ad
Legals
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
188.26
+2.26 (+1.22%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 26, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
December 14, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Exposures
Product Safety
Alnylam Ranks #1 in Boston Globe’s Top Places to Work List for 2021
December 02, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentations at Upcoming Investor Conferences
November 23, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Read Why Analysts Are Going Bullish On This Large-Cap Pharma Stock
November 22, 2021
RBC Capital has upgraded Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) to Outperform from Sector Perform with a price target of $225, up from $144. While M...
Via
Benzinga
How Alnylam Pharmaceuticals Could Take On Pfizer With A 'Catalyst-Rich' 2022
November 22, 2021
Alnylam is working on a drug that could tackle transthyretin cardiomyopathy.
Via
Investor's Business Daily
Expert Ratings For Alnylam Pharmaceuticals
November 22, 2021
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021
November 22, 2021
Upgrades According to Evercore ISI Group, the prior rating for Kimco Realty Corp (NYSE:
Via
Benzinga
10 Biggest Price Target Changes For Monday
November 22, 2021
MKM Partners cut Activision Blizzard, Inc. (NASDAQ:A...
Via
Benzinga
Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day
November 19, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
November 18, 2021
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation...
Via
Benzinga
Dicerna Stock Rockets On Novo Nordisk's $3.3 Billion Takeover Plan
November 18, 2021
Novo Nordisk is buying an RNA interference company.
Via
Investor's Business Daily
Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021
November 13, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Virtual R&D Day
November 12, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension
November 08, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
November 05, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Named a Science Magazine Top Employer for Third Consecutive Year
November 01, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Where Alnylam Pharmaceuticals Stands With Analysts
November 01, 2021
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ra...
Via
Benzinga
Alnylam Pharmaceuticals, inc (ALNY) Q3 2021 Earnings Call Transcript
October 29, 2021
ALNY earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Alnylam Pharmaceuticals Stock Is Tanking This Week
October 29, 2021
The company missed analysts' Q3 revenue expectations and announced the departure of its CEO.
Via
The Motley Fool
Why Alnylam Pharmaceuticals Is Crashing Today
October 28, 2021
The company's earnings fell short of expectations and its CEO is leaving.
Via
The Motley Fool
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
66 Biggest Movers From Yesterday
October 29, 2021
Gainers HCW Biologics Inc. (NASDAQ: HCWB) shares surged 62% to close at $4.73 on Thursday after the company announced that it has been cleared by the U.S. Food and Drug...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
October 28, 2021
Gainers Kiromic BioPharma (NASDAQ:KRBP) stock moved upwards by 21.62% to $2.25 during Thursday's regular session. Trading volume for Kiromic BioPharma's stock is...
Via
Benzinga
Alnylam Stock Dives As Sales Growth Falters And CEO John Maraganore Plans Exit
October 28, 2021
Alnylam fell on a disappointing quarter and plans for CEO John Maraganore to exit.
Via
Investor's Business Daily
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
October 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In...
Via
Benzinga
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
October 28, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Planned CEO Leadership Transition
October 28, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
October 27, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
October 24, 2021
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.